logo
logo

Ucello Therapeutics Completes Us$25 Million Series A Financing

Feb 10, 2022•over 3 years ago

Amount Raised

$25 Million

Round Type

series a

San Diego

Description

Ucello Therapeutics ("Ucello"), a biotechnology company developing universal CAR-T therapies, announced the successful completion of a US$25 million Series A financing.

Company Information

Company

Ucello Therapeutics

Location

San Diego, California, United States

About

Ucello Therapeutics, established in December 2020 in Chengdu Tianfu International Bio-town, is a privately held biotechnology company focused on the development of allogeneic cell therapies. Powered by its proprietary universal CAR-T cell technology platform CBT-X20, Ucello has developed several "off-the-shelf" cell therapy pipelines for the treatment of solid tumors and hematologic malignancies, and potentially change the landscape of CAR-T cell therapy.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech